Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02407457 · ClinicalTrials.gov registry record · NA
Post-Market Study to Assess Outcomes of Patients Treated With AFX System Compared to Other EVAR Devices
A NA study, sponsored by Endologix.
- Completed
- Registry status
- NA
- Development phase
- 455
- Enrollment target
NCT02407457 is a NA study that has completed, run by Endologix. The registered enrollment target is 455 participants.
The verdict
NCT02407457, a NA study, has completed, sponsored by Endologix.
- COMPLETED
- Registry status
- NA
- Development phase
- 455 participants
- Enrollment target
Study Summary
The objective of this post-market trial is to evaluate Endologix AFX endovascular AAA system with anatomical fixation against other approved Endovascular systems with proximal fixation. Multiple U.S clinical centers will be involved in the trial to include a broad range of experience. Imaging data will be evaluated by an independent core lab.
Interventions
- DEVICE FDA Approved EVAR AAA Graft Systems
- DEVICE AFX EVAR AAA Graft System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 455 participants |
| Start Date | 2015-03 |
| Est. Completion | 2022-10 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02407457
The ClinicalTrials.gov registry entry for NCT02407457 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 455 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Endologix, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which FDA Approved EVAR AAA Graft Systems is the first listed.
NCT02407457 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02407457 about?
NCT02407457 is a clinical study titled "Post-Market Study to Assess Outcomes of Patients Treated With AFX System Compared to Other EVAR Devices". The objective of this post-market trial is to evaluate Endologix AFX endovascular AAA system with anatomical fixation against other approved Endovascular systems with proximal fixation. Multiple U.S clinical centers will be involved in the trial to include a broad range of experience. Imaging data w...
What is the current status of trial NCT02407457?
This trial is currently completed. It is a NA study. The enrollment target is 455 participants. The study started on 2015-03. Estimated completion is 2022-10.
What interventions are being tested in trial NCT02407457?
The interventions under investigation include: FDA Approved EVAR AAA Graft Systems (DEVICE), AFX EVAR AAA Graft System (DEVICE).
Who is sponsoring clinical trial NCT02407457?
This trial is sponsored by Endologix, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.